Industry supervisors envisage Japan to be the second fastest growing mature marketplace for solid dose drugs in 2019 followed by the United States. The findings represent a considerable year-on-year improvement in outlook for pharma in Japan with expected growth of solid dose formulations improving by more than 10% with generic drug classes highlighted Significantly, it ranks ahead of all EU nations and Korea. The report concludes that Japan is a ripened country for growth across a number of product classes, but the enduring winners of regulatory changes and innovative R&D remain hard to pick.
Reference Link: https://biospectrumasia.com/news/50/12865/japan-second-fastest-pharma-growth-in-2019-cphi-report.html
